Thus, continuous stimulation with IL-15 hyperagonist over time could lead to NK cells becoming hypo-responsive and therefore incapable of killing HLA-I low/negative melanoma cells (62), and also to dysfunctional TRM-like cells being unable to eliminate HLA-I positive melanoma cells (31, 53). The gene discussed is IL15; the disease is melanoma.